Clinical relevance and concordance of HER2 status in local and central testing—an analysis of 1581 HER2-positive breast carcinomas over 12 years

Baselga, 2009, Novel anticancer targets: revisiting ERBB2 and discovering ERBB3, Nat Rev Cancer, 9, 463, 10.1038/nrc2656 Slamon, 1987, Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene, Science, 235, 177, 10.1126/science.3798106 Gschwind, 2004, The discovery of receptor tyrosine kinases: targets for cancer therapy, Nat Rev Cancer, 4, 361, 10.1038/nrc1360 Tolaney, 2014, New HER2-positive targeting agents in clinical practice, Curr Oncol Rep, 16, 359, 10.1007/s11912-013-0359-8 Wolff, 2013, Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update, J Clin Oncol, 31, 3997, 10.1200/JCO.2013.50.9984 Wolff, 2007, American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer, J Clin Oncol, 25, 118, 10.1200/JCO.2006.09.2775 Paik, 2002, Real-world performance of HER2 testing—National Surgical Adjuvant Breast and Bowel Project experience, J Natl Cancer Inst, 94, 852, 10.1093/jnci/94.11.852 Paik, 2008, HER2 status and benefit from adjuvant trastuzumab in breast cancer, N Engl J Med, 358, 1409, 10.1056/NEJMc0801440 Romond, 2005, Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer, N Engl J Med, 353, 1673, 10.1056/NEJMoa052122 Loi, 2016, Effects of estrogen receptor and human epidermal growth factor receptor-2 levels on the efficacy of trastuzumab: a secondary analysis of the HERA Trial, JAMA Oncol, 2, 1040, 10.1001/jamaoncol.2016.0339 von Minckwitz, 2008, Neoadjuvant vinorelbine-capecitabine versus docetaxel-doxorubicin-cyclophosphamide in early nonresponsive breast cancer: phase III randomized GeparTrio Trial, J Natl Cancer Inst, 100, 542, 10.1093/jnci/djn085 von Minckwitz, 2008, Intensified neoadjuvant chemotherapy in early-responding breast cancer: phase III randomized GeparTrio Study, J Natl Cancer Inst, 100, 552, 10.1093/jnci/djn089 von Minckwitz, 2005, In vivo chemosensitivity-adapted preoperative chemotherapy in patients with early-stage breast cancer: the GEPARTRIO pilot study, Ann Oncol, 16, 56, 10.1093/annonc/mdi001 von Minckwitz, 2010, Capecitabine in addition to anthracycline- and taxane-based neoadjuvant treatment in patients with primary breast cancer: phase III GeparQuattro study, J Clin Oncol, 28, 2015, 10.1200/JCO.2009.23.8303 Untch, 2010, Neoadjuvant treatment with trastuzumab in HER2-positive breast cancer: results from the GeparQuattro study, J Clin Oncol, 28, 2024, 10.1200/JCO.2009.23.8451 Untch, 2012, Lapatinib versus trastuzumab in combination with neoadjuvant anthracycline-taxane-based chemotherapy (GeparQuinto, GBG 44): a randomised phase 3 trial, Lancet Oncol, 13, 135, 10.1016/S1470-2045(11)70397-7 Gerber, 2013, Neoadjuvant bevacizumab and anthracycline-taxane-based chemotherapy in 678 triple-negative primary breast cancers; results from the geparquinto study (GBG 44), Ann Oncol, 24, 2978, 10.1093/annonc/mdt361 von Minckwitz, 2012, Neoadjuvant chemotherapy and bevacizumab for HER2-negative breast cancer, N Engl J Med, 366, 299, 10.1056/NEJMoa1111065 Huober, 2013, Neoadjuvant chemotherapy with paclitaxel and everolimus in breast cancer patients with non-responsive tumours to epirubicin/cyclophosphamide (EC) +/- bevacizumab - results of the randomised GeparQuinto study (GBG 44), Eur J Cancer, 49, 2284, 10.1016/j.ejca.2013.02.027 von Minckwitz, 2014, Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial, Lancet Oncol, 15, 747, 10.1016/S1470-2045(14)70160-3 Untch, 2016, Nab-paclitaxel versus solvent-based paclitaxel in neoadjuvant chemotherapy for early breast cancer (GeparSepto-GBG 69): a randomised, phase 3 trial, Lancet Oncol, 17, 345, 10.1016/S1470-2045(15)00542-2 McShane, 2006, REporting recommendations for tumor MARKer prognostic studies (REMARK), Breast Cancer Res Treat, 100, 229, 10.1007/s10549-006-9242-8 Noske, 2011, Comparison of different approaches for assessment of HER2 expression on protein and mRNA level: prediction of chemotherapy response in the neoadjuvant GeparTrio trial (NCT00544765), Breast Cancer Res Treat, 126, 109, 10.1007/s10549-010-1316-y Denkert, 2013, HER2 and ESR1 mRNA expression levels and response to neoadjuvant trastuzumab plus chemotherapy in patients with primary breast cancer, Breast Cancer Res, 15, R11, 10.1186/bcr3384 Ingold Heppner, 2016, Tumor-infiltrating lymphocytes: a predictive and prognostic biomarker in neoadjuvant treated HER2-positive breast cancer, Clin Cancer Res, 22, 5747, 10.1158/1078-0432.CCR-15-2338 Müller, 2011, Quantitative determination of estrogen receptor, progesterone receptor, and HER2 mRNA in formalin-fixed paraffin-embedded tissue—a new option for predictive biomarker assessment in breast cancer, Diagn Mol Pathol, 20, 1, 10.1097/PDM.0b013e3181e3630c Bohmann, 2009, RNA extraction from archival formalin-fixed paraffin-embedded tissue: a comparison of manual, semiautomated, and fully automated purification methods, Clin Chem, 55, 1719, 10.1373/clinchem.2008.122572 Denkert C, Loibl S, Noske A et al. Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer. J Clin Oncol28:105–113. Hennig, 2010, Automated extraction of DNA and RNA from a single formalin-fixed paraffin-embedded tissue section for analysis of both single-nucleotide polymorphisms and mRNA expression, Clin Chem, 56, 1845, 10.1373/clinchem.2010.151233 Perez, 2014, HER2 testing: current status and future directions, Cancer Treat Rev, 40, 276, 10.1016/j.ctrv.2013.09.001 Kaufman, 2014, Assessing the discordance rate between local and central HER2 testing in women with locally determined HER2-negative breast cancer, Cancer, 120, 2657, 10.1002/cncr.28710 McCullough, 2014, Central pathology laboratory review of HER2 and ER in early breast cancer: an ALTTO trial [BIG 2-06/NCCTG N063D (Alliance)] ring study, Breast Cancer Res Treat, 143, 485, 10.1007/s10549-013-2827-0 Perez, 2006, HER2 testing by local, central, and reference laboratories in specimens from the North Central Cancer Treatment Group N9831 intergroup adjuvant trial, J Clin Oncol, 24, 3032, 10.1200/JCO.2005.03.4744 Choritz, 2011, Quality assessment of HER2 testing by monitoring of positivity rates, Virchows Arch, 459, 283, 10.1007/s00428-011-1132-8